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Abstract
Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, including mechanism
of action, cost, and reasons for lack of benefit. Data sources: Articles were gathered from MEDLINE, Cochrane
Reviews, and PubMed databases (1980-2021). Abstracts from scientific meetings were considered. Search terms included
ischemic stroke, aspirin, clopidogrel, dipyridamole, ticagrelor, cilostazol, prasugrel, glycoprotein IIb/IIIa inhibitors.
Study selection and data extraction: English-language original and review articles were evaluated. Guidelines from
multiple countries were reviewed. Articles were evaluated independently by 2 authors. Data synthesis: An abundance
of evidence supports aspirin and clopidogrel use for secondary stroke prevention. In the acute phase (first 21 days
postinitial stroke), these medications have higher efficacy for preventing further stroke when combined, but long-term
combination therapy is associated with higher hemorrhage rates. Antiplatelet treatment failure is influenced by poor
adherence and genetic polymorphisms. Antiplatelet agents such as cilostazol may provide extra benefit over clopidogrel
and aspirin, in certain racial groups, but further research in more diverse ethnic populations is needed. Relevance to
patient care and clinical practice: This review presents the data available on the use of different antiplatelet agents
poststroke. Dual therapy, recurrence after initiation of secondary preventative therapy, and areas for future research
are discussed. Conclusions: Although good evidence exists for the use of certain antiplatelet agents postischemic
stroke, there are considerable opportunities for future research to investigate personalized therapies. These include
screening patients for platelet polymorphisms that confer antiplatelet resistance and for randomized trials including
more racially diverse populations.
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Introduction
Stroke is the second most common cause of death worldwide and one of the leading causes of long-term disability
globally.1 Over the last 25 years, there has been a global
reduction in the rate of death and age-adjusted stroke prevalence, but overall, the absolute numbers of stroke cases
have increased as populations have developed greater longevity.1 Ischemic stroke is, by far, the most common cause
of stroke worldwide, accounting for 10 times more strokes
than hemorrhagic strokes in higher income countries,2 but
with much less difference observed in lower income countries.3 Although the rate of stroke deaths is decreasing, it is
believed that up to 50% of stroke-related deaths are attributable to poorly managed modifiable risk factors.4
Management of hypertension, hypercholesterolemia, diabetes, smoking, and cardiac arrhythmias such as atrial fibrillation all have a considerable evidence base for reducing
stroke occurrence and recurrence.5

The risk of recurrent ischemic stroke events in the first
30 days is high with 1 in 25 people having a recurrent stroke
in this time frame.6 Therefore, treatments employed to
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Figure 1. Antiplatelet agents and their mechanisms of action on the platelet. This figure highlights the site of action for multiple
antiplatelet agents. This figure highlights how the multiple sites of action may contribute to the increased efficacy when certain
antiplatelet agents are combined. Created with BioRender.com.
Abbreviations: ADP, adenosine diphosphate; COX, cyclo-oxygenase; TXA2, thromboxane A2.

reduce this initial risk can have considerable impact on
reducing morbidity and mortality. Antiplatelet agents are
indicated when the cause of the ischemic stroke is determined to be noncardioembolic antiplatelets modify the risk
of further stroke events and reduce the rate of death in this
acute period and in the long term.7
The most used antiplatelet agents worldwide include aspirin, clopidogrel, and dipyridamol.8 All have high-level evidence for the prevention of stroke recurrence. Unfortunately,
there is a population of patients who exhibit “resistance” to
these medications (have ischemic events while on an antiplatelet agent), develop adverse effects from use, or develop
allergic reactions.9 Combining antiplatelets is associated with
increased risk of bleeding when used for long-term prevention, although this increased risk is often outweighed by
decreased stroke recurrence in the short term.10,11 As a result,
the treatment provider is faced with a difficult decision about
how best to treat a patient with further stroke events who has
already received one antiplatelet agent.
The class of medications that have antiplatelet activity is
large with a diverse set of mechanistic actions. This offers
the opportunity to utilize alternative antiplatelet agents if a

patient has an ischemic stroke while on first-line therapies.
The decision about which antiplatelet agent to use when a
more commonly used drug has undesired effects is difficult
due to limited data comparing antiplatelet agents head-tohead.10 Figure 1 highlights the different mechanisms attributed to the action of several antiplatelet agents.
In this review article, we have summarized the evidence
available for each antiplatelet drug used in the treatment of
ischemic stroke. We have then offered suggestions for alternative therapeutic options when faced with recurrent stroke.
We conclude with a description of what the future may hold
for antiplatelet therapies in ischemic stroke.

Methods of Review
Articles were gathered from MEDLINE, Cochrane Reviews,
and PubMed databases. The literature search included all
article published between January 1980 and September
2021. Abstracts from scientific meetings were considered.
Search terms included ischemic stroke, aspirin, clopidogrel,
dipyridamole, ticagrelor, cilostazol, prasugrel, and glycoprotein IIb/IIIa inhibitors. Study selection was limited to
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English-language original and review articles. Guidelines
from America, United Kingdom, Canada, and China were
reviewed. When presenting clinical data on each antiplatelet agent, we have focused on randomized control trial
(RCT) or systematic review levels of evidence.

Antiplatelet Drugs
Aspirin
Aspirin is the most widely studied antiplatelet agent that is
used in the acute phase and in secondary prevention of ischemic stroke, either alone or in combination therapy with
other antiplatelet agents.12 Aspirin is an essential World
Health Organization (WHO) medication, generally well tolerated and inexpensive. Aspirin exhibits its effects by irreversibly inhibiting cyclo-oxygenase (COX), which reduces
platelet aggregation by inhibiting the synthesis of the procoagulant thromboxane A2 (TXA2).
Multiple studies have demonstrated the efficacy of aspirin in the acute phase of ischemic stroke.7 A meta-analysis
of 40 000 patients from the International Stroke Trial (IST)
and Chinese Acute Stroke Trial (CAST) compared aspirin
(160-300 mg) with placebo or no medication, for a total of
2 to 4 weeks.13 Aspirin administration within 48 hours of
stroke led to a significant reduction in the overall risk of
early recurrent stroke (7 per 1000) and death (4 per 1000),
with no significant increase in hemorrhagic stroke or transformation during this timeframe. This corresponds to a 30%
odds reduction of recurrent ischemic stroke (number needed
to treat [NNT] = 140).7 These studies provide the main evidence that supports the use of aspirin in the acute setting,
including the timeframe at which the risk of recurrent stroke
is the highest.14 The CAST recruited 20 000 patients across
413 Chinese hospitals, whilst IST included a similar number of patients from 36 different countries, around 80% of
whom were treated in European Hospitals. The population
in the CAST study had half the rate of mortality during
inpatient admission compared with IST, which the authors
attribute to the exclusion criteria of severe strokes, lower
mean age of participants, and the different etiologies of
stroke (ie, intracranial vs extracranial disease).15
In those receiving thrombolysis with alteplase, it is recommended to delay aspirin administration for 24 hours. In
the Antiplatelet Therapy in Combination with Recombinant
t-PA Thrombolysis in Ischemic Stroke (ARTIS) trial, early
aspirin administration was shown to not improve outcomes
at 3 months as judged by mRS score of 0 to 2 (relative risk
[RR] = 0.94, 95% CI = 0.82-1.09), and increased the risk
of intracerebral hemorrhage (ICH) when co-administered
with alteplase, compared with no additional treatment (RR
= 2.78, 95% CI = 1.01-7.63).16
The 2009 Antithrombotic Trialists’ collaboration (ATC)
meta-analysis included a subset of 6170 patients taking
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aspirin as a secondary preventative agent following ischemic stroke or TIA.17 Aspirin compared with placebo
showed a reduction of 17% (95% CI = 4%-28%) in any
stroke, but with an increase in hemorrhagic stroke (RR =
1.9, 95% CI = 1.06-3.4) and GI bleeding (RR = 2.69, 95%
CI = 1.25-5.76) during follow-up periods ranging from 1 to
6 years.17 There remains net benefit in taking aspirin as a
secondary preventative,18 which holds true when taking age
and sex into account. Dosing regimens have been extensively investigated, with the earlier 2002 collaboration finding that a daily dose of 75 to 150 mg of aspirin confers
equivalent benefit long-term without the added risk of
bleeding of higher doses.19
Although there is good evidence for the efficacy of aspirin as both an acute treatment for ischemic stroke and secondary prevention, it is not licensed as a primary prevention
agent for stroke in the United Kingdom.20 Although aspirin
is not licensed for this indication in the United Kingdom, it
is recommended by the American Heart Association and
American Stroke Association (AHA/ASA) as a primary
preventative agent in cardiovascular disease, including
stroke, in patients with a 10-year cardiovascular risk score
of above 10% (level IIa evidence).21 A 2020 meta-analysis
of 157 054 participants across 11 studies examined the risk
of stroke in patients without cardiovascular disease who
were taking 75 to 500 mg of aspirin daily as primary prevention.22 The studies included patients varying from low to
moderate risk of cardiovascular disease, with risk factors
including hypertension and diabetes, who were followed up
for at least 1 year. Although aspirin was associated with a
significant reduction in myocardial infarction, there was no
reduction in nonfatal strokes (odds ratio [OR] = 0.94, 95%
CI = 0.85-1.04), nor in cardiovascular mortality rates.
However, there was an increased risk of hemorrhagic
strokes (OR = 1.29, 95% CI = 1.06-1.56, number needed
to harm [NNH] = 8333) and of major gastrointestinal
bleeds in those taking aspirin (OR = 1.83, 95% CI = 1.432.35, NNH = 2040). These data suggest that the place for
aspirin treatment in stroke is secondary prevention rather
than primary prevention.
Not all patients respond to aspirin. Aspirin treatment
failure can be described clinically, in the form of recurrent
vascular events such as TIA, stroke and myocardial infarction (MI), as well as biochemically, as measured by elevated
TXA2 levels and rapid platelet plug formation. Despite the
10-day platelet turnover time required to restore TXA2 levels post-COX inhibition, aspirin treatment failure is thought
to occur with a frequency of 12.9%, as defined by vascular
events during aspirin treatment.23 The heterogeneity in
response to aspirin can be explained by several mechanisms, including poor medication adherence, poor absorption, drug interactions, insufficient dosing, and alternative
pathways of platelet activation, including COX polymorphisms and the possible upregulation of COX-2 expression
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during periods of inflammation, which bypasses inhibition
by aspirin to produce TXA2.23,24 Genetic differences in
other components of thrombotic pathways are thought to
contribute to aspirin resistance, examples being polymorphisms of platelet membrane glycoproteins, the P2Y1 gene,
and von Willebrand Factor.25 However, the most common
cause of aspirin treatment failure has been shown to be poor
adherence.26

Clopidogrel
Clopidogrel is a second generation thienopyridine antiplatelet agent. It is a prodrug that is metabolized to its active
form by the hepatic cytochrome P450 system. The active
metabolite is an irreversible inhibitor of the P2Y12 class of
adenosine diphosphate (ADP) receptors on the surface of
platelets, preventing ADP-mediated activation of the downstream glycoprotein IIb/IIIa complex, resulting in reduced
platelet aggregation. Genetic polymorphisms in the
enzymes involved in clopidogrel metabolism contribute to
variation in response to clopidogrel between individuals.27
Clopidogrel is licensed for the management of ischemic
stroke in both the acute phase if patients are known to be
aspirin allergic and as long-term secondary prevention.
Clopidogrel loading at a dose of 300 or 600 mg is recommended as the acute treatment,11,28 followed by 75 mg daily
long-term.29 A 300 mg loading dose of clopidogrel in
patients with moderate to severe stroke (National Institutes
of Health Stroke Scale [NIHSS] ≥4) within 6 hours of
admission has been shown to be safe and efficacious, with
one retrospective study (n = 1011) showing no difference
in poor functional outcomes as defined by mRS >2 on discharge (OR = 0.71, 95% CI = 0.46-1.09), and lower rates
of neurological worsening as defined by an NIHSS increase
≥2 in any 24-hour period, although the latter was no longer
statistically significant after adjusting for baseline NIHSS.28
The CAPRIE trial first compared clopidogrel monotherapy with aspirin monotherapy for prevention of vascular
events (ischemic stroke, myocardial infarction, or vascular
death) in 19 185 patients with established atherosclerotic
vascular disease.30 This included 6431 patients with recent
ischemic stroke. Across all patients, clopidogrel lead to an
8.7% relative risk reduction (RRR), 95% CI = 0.3%-16.5%,
P = 0.043, in vascular events compared with aspirin alone,
without an increase in adverse events. However, for the subset of patients with previous ischemic stroke, there was no
significant difference in vascular events for patients treated
with clopidogrel compared with aspirin (RRR = 7.3%,
95% CI = −5.7% to 18.7%, P = 0.26). Moreover, no significant difference was seen between aspirin and clopidogrel for prevention of ischemic stroke in both the overall
cohort and the previous stroke cohort.30 Following this, the
MATCH trial compared dual antiplatelet therapy (DAPT)
with aspirin plus clopidogrel, to clopidogrel monotherapy
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for secondary prevention in 7599 patients with recent ischemic stroke or high-risk TIA with ≥1 additional vascular
risk factor. In patients treated with DAPT for 18 months, no
significant reduction in stroke was found and there was a
trend toward more major bleeding events, although this
trend was not statistically significant.29 Therefore, when
summarizing the results of the MATCH, CHANCE, and
POINT trials, the window of benefit for DAPT in preventing recurrent ischemic strokes would appear to be only in
the acute poststroke phase.
In summary, the consensus among international guidelines is that after the initial poststroke phase (21 days), clopidogrel alone (or aspirin alone) is as effective and safer than
DAPT for secondary prevention of ischemic stroke.

Dipyridamole
Dipyridamole is an antiplatelet drug that has been shown to
have multiple mechanisms of action, including inhibiting
cAMP-phosphodiesterase, blocking the reuptake and breakdown of adenosine by platelets, and enhancing PGI2
biosynthesis.31
The drug has been shown in multiple RCTs and metaanalyses to reduce the risk of further vascular events in
patients with previous ischemic stroke.32-37 Several trials
have shown that dipyridamole alone can reduce the rate of
vascular events in patients who have had a previous ischemic stroke,38,39 but when combined with low-dose aspirin, this effect is greater than when the drugs are given
separately.36
Interestingly, and typified by the Cochrane meta-analysis by De Schryver et al, while dipyridamole reduces vascular events compared with control (RR = 0.88, 95% CI =
0.81-0.95), it does not appear to have an effect on the incidence of vascular deaths poststroke.32,36,37 Subgroup analysis of patients who have had a stroke was performed in this
meta-analysis to identify whether this group benefited to a
greater or lesser extent from dipyridamole and aspirin combination therapy than stroke-naive patients, but the drug
appears to have equal effect on all subgroups of ischemic
stroke.33
When comparing dipyridamole and aspirin against clopidogrel for secondary prevention of vascular events poststroke, a single-center UK-based study found that in the
first year after stroke, dipyridamole and aspirin therapy
have a greater effect at reducing further vascular events
(study size n = 3572).34 Clopidogrel has been shown to be
the better therapy at reducing vascular events after 1 year,
albeit in a retrospective cohort analysis.34 Although aspirin
combined with dipyridamole has not been shown to be inferior to clopidogrel in preventing further stroke events, the
Prevention Regimen for Effectively Avoiding Second
Strokes international (PRoFESS), a multicenter trial (n =
20 332) showed a higher likelihood for major hemorrhage
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in patients treated with both aspirin and dipyridamole (4.1%
vs 3.6%, hazard ratio [HR] = 1.15, 95% CI = 1.001.32).32,37 This effect is seen after the initial acute stroke
phase as detailed in the clopidogrel section of this review.
The propensity to develop headaches while taking dipyridamole is another factor to consider when using this drug
as stroke secondary prevention. Up to 40% of patients taking dipyridamole report headaches,40 with up to 5.9% of
patients in the PRoFESS trial stopping the drug for this
reason.32
In summary, dipyridamole in combination with aspirin
remains a good treatment for the secondary prevention of
ischemic stroke, but the increased risk of bleeding and
headaches that are associated with the medication indicates
that in current practice, the medication is used less
frequently.

Prasugrel
Prasugrel is a third-generation thienopyridine and a prodrug
which converts to an active metabolite, R-138727, which
irreversibly inhibits the platelet P2Y12 receptor.41 This prevents the binding of ADP and prevents activation of the glycoprotein IIb/IIIa complex.41 Unlike clopidogrel, loss of
function polymorphisms in CYP2C19 and CYP2C9 are not
associated with reduced pharmaco-availability of the active
metabolite of prasugrel.42
The initial evidence for prasugrel was established
through large multicenter clinical trials in acute coronary
syndromes (ACS). The TRITON-TIMI-38 study, a phase 3
randomized clinical trial, compared clopidogrel (300 mg
loading dose and 75 mg daily maintenance dose) versus
prasugrel (60 mg loading dose and 10 mg daily maintenance dose) in patients with ACS undergoing percutaneous
coronary intervention (PCI), n = 13 608.43 While prasugrel
therapy was associated with reduced rates of myocardial
infarction and stent thrombosis compared with clopidogrel
(7.4% vs 9.7%, HR = 0.76, 95% CI = 0.67-0.85), there
was a higher rate of nonfatal (1.1% vs 0.9%, HR = 1.25,
95% CI = 0.87-1.81) and fatal (0.4% vs 0.1%; HR = 4.19,
95% CI = 1.58-11.11) bleeding events over a follow-up
period of 6 to 15 months.44 Subgroup analysis indicated
that individuals who had at least one of either a history of
stroke or TIA were ≥75 years of age or weighed <60 kg
had higher rates of bleeding and consequently either no net
benefit or a net harm from prasugrel.43 As such, prasugrel
is currently contraindicated in individuals with a history of
stroke or TIA. In contrast to this, TRILOGY-ACS (n =
7243) found that a dose of prasugrel (10 mg/day in those
weighing ≥ 60 kg or 5 mg/day in those weighing <60 kg)
given for greater than 12 months in patients aged 75 years
or above, medically treated for ACS and without prior
stroke or TIA, was associated with a lower risk of ischemic
stroke compared with clopidogrel therapy (75 mg/day).45
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However, this was an underpowered study with a low overall number of strokes.
There are several contention issues with the above studies, including the dose of prasugrel used and the dangers of
extrapolating results from ACS trials to ischemic stroke. As
such, the PRASTRO-I study in Japan randomized 3753
patients aged <75 and weighing >50 kg with noncardioembolic stroke to either prasugrel (3.75 mg/day) or clopidogrel (75 mg/day) for 96 to 104 weeks.46 While there were a
similar number of ischemic strokes, myocardial infarcts,
and hemorrhagic strokes between the 2 treatment groups,
the noninferiority of prasugrel to clopidogrel was not demonstrated. The PRASTRO-II study investigated 2 different
doses of prasugrel (2.5 mg/day or 3.75 mg/day) versus clopidogrel (50 mg/day) in Japanese patients aged ≥75 and
weighing ≤50 kg) and found no significant differences in
the rates of ischemic stroke, myocardial infarction, vascular
death, or major bleeding.47 As such, there is not enough evidence to support the use of prasugrel instead of using clopidogrel in individuals with a history of ischemic stroke or
TIA.

Ticagrelor
Ticagrelor exerts its potent antiplatelet activity by reversibly binding to and inhibiting the platelet adenosine diphosphate P2Y12 receptor. Its antithrombotic effects are well
established in the management of patients with ACS.48
However, in some of the earlier ACS randomized controlled
trials, the effect on stroke risk was mixed. In the PLATO
study that randomized 18 624 patients with moderate to
high-risk ACS undergoing PCI, to either ticagrelor or clopidogrel, ticagrelor was associated with reduced death from
all vascular causes (HR = 0.84; CI = 0.77-0.92; P ≤
0.001).49 This was attributed mainly to reduced myocardial
infarction, but not to a reduction in stroke risk. In fact,
patients in the ticagrelor arm experienced a nonsignificantly
higher rate of stroke (1.5% vs 1.3%, HR = 1.17; CI = 0.911.52; P = 0.22) and fatal intracranial hemorrhage in particular (0.1% vs 0.01%, P = 0.02).49
These concerns, however, were not born out in RCTs in
stroke patients. The SOCRATES study randomized 13 199
patients with mild acute ischemic stroke (AIS) (NIHSS <
5) or high-risk TIA (ABCD2 score > 4) to either high-dose
aspirin (300 mg loading, 100 mg maintenance) or ticagrelor
(180 mg loading, 90 mg twice daily maintenance) for 90
days.50 Ticagrelor was nonsuperior to aspirin monotherapy
for the primary endpoint of first occurrence of a composite
of vascular endpoints, for example, stroke, MI, death (7.5%
aspirin vs 6.7% ticagrelor, HR = 0.89; 95% CI = 0.781.01; P = 0.07), but importantly was not found to be associated with increased risk of hemorrhagic stroke (0.3% vs
0.2% respectively). The subsequent THALES study51
investigated the combination of ticagrelor and aspirin with
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aspirin alone in this same population (n = 11 016). They
found the combination of ticagrelor and aspirin was associated with reduced rates of stroke or death within 30 days
compared with aspirin alone (5.5% vs 6.6%; HR = 0.83,
95% CI = 0.71-0.96; P = 0.02; NNT = 91) but slightly
higher rates of major bleeding events (0.5% vs 0.1%, HR =
3.99, 95% CI = 1.74-9.14, P = 0.001) and intracranial
hemorrhage (0.4% vs 0.1%, HR = 3.33, 95% CI = 1.348.28, P = 0.01). Ticagrelor has also been associated with
both bradycardia and increased dyspnea when compared
with other antiplatelet agents, which also need to be considered when using this medication.52 No head-to-head trials
with clopidogrel either alone or in combination with aspirin
have been undertaken, but due to the lack of CYP2C19mediated activity, ticagrelor may have benefits in clopidogrel-resistant populations. Currently, the drug is not licensed
in the United States or United Kingdom.

Ticlopidine
Ticlopidine is a thienopyridine derivative prodrug, like
clopidogrel. Its active metabolite selectively and irreversibly inhibits the ADP-binding site on the P2Y12 receptor and
thus ADP-induced platelet aggregation.53 There have been 3
RCTs looking at ticlopidine in the prevention of stroke in
patients with a recent TIA or minor stroke. The Canadian
American Ticlopidine Study (CATS), n = 1072, compared
500 mg/day ticlopidine with placebo and found an RRR
with ticlopidine for stoke, MI, and vascular death of 30.2%
(95% CI = 7.5%-48.3%, P = 0.006) at 3 years in those
randomized to ticlopidine.54 In this study, no comparison
was made with aspirin. The Ticlopidine Aspirin Stroke
Study (TASS), n = 3069, compared 500 mg/day ticlopidine
with 1300 mg/day aspirin and found a 21% risk reduction in
the development of fatal and nonfatal stroke with ticlopidine compared with aspirin at 3 years (95% CI = 4%-38%).55
Subgroup analysis of the TASS study showed a 60.8%
reduction in fatal and nonfatal stroke risk with ticlopidine in
nonwhite patients.56 In light of these findings, a subsequent
study compared 500 mg/day ticlopidine with 650 mg/day
aspirin in black patients, given the high stroke burden and
underrepresentation of this population in clinical trials.57
However, the study was stopped after 6.5 years, as futility
analysis showed that ticlopidine had a less than 1% chance
of being superior to aspirin. A recent population-based
cohort study in Taiwan (n = 2585) found that patients with
ischemic stroke who were treated with 100 mg/d aspirin had
lower rates of recurrent stroke at 3-year follow-up compared with those treated with 75 mg/day clopidogrel (2.03%
vs 2.55%, HR = 2.27, 95% CI = 1.02-5.07). About 200
mg/day of ticlopidine was found to be noninferior to aspirin
(1.48% vs 2.03%, HR = 0.62, 95% CI = 0.08-4.86).58
Common adverse effects of ticlopidine include diarrhea
(23.6% in CATS and 20.4% in TASS) and rash (17.0% in
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CATS and 11.9% in TASS). Furthermore, ticlopidine is
associated with the development of severe but reversible
neutropenia (0.03% in CATS and 0.9% in TASS). At the
lower dose used in the cohort study in Taiwan, no patients
developed neutropenia, suggesting that this effect may be
dose-related. Nevertheless, patients on ticlopidine require
regular blood monitoring, particularly in the first few
months of treatment.56
Ticlopidine is an effective drug for the prevention of
ischemic stroke. However, its use is limited by potentially
severe hematological adverse effects. Therefore, ticlopidine
is currently not licensed or recommended for use in ischemic stroke within the United Kingdom, United States, or
most of mainland Europe. Further studies using lower doses
of ticlopidine are warranted. In particular, studies focussing
on a broader range of nonwhite populations, for example
East Asian populations, where clopidogrel, but not ticlopidine,59 is known to be less effective due to higher carrier
rates of the CYP2C19 loss-of-function allele.60

Cilostazol
Cilostazol is a selective inhibitor of phosphodiesterase 3,
which increases the activation of intracellular cAMP and
thereby inhibits platelet aggregation. As well as the action
on platelet aggregation, cilostazol also dilates blood vessels.61 It is assumed to have a weak antiplatelet effect in
acute stages of stroke treatment, but the combined vasodilatory and antiplatelet effect is thought to be the underlying
mechanism leading to long-term stroke prevention.62
There are 2 large trials with large cohorts that have studied the effect of cilostazol in ischemic stroke management,
PICASSO and CSPS.com. In the CSPS.com trial, 1879
Japanese patients with high-risk noncardioembolic ischemic stroke were enrolled between 8 and 180 days after
stroke. Combination of cilostazol with aspirin or clopidogrel reduced the annual incidence of recurrent ischemic
stroke by half compared with monotherapy (2.2% dual therapy with cilostazol vs 4.5% monotherapy, HR = 0.49, 95%
CI = 0.31-0.76), without increasing the annual risk of
severe or life-threatening bleeding (0.6% dual vs 0.9%
monotherapy, HR = 0.66, 95% CI = 0.27-1.60).63 The
PICASSO trial (n = 1534) showed cilostazol may be beneficial for ischemic stroke patients with multiple cerebral
microbleeds and those patients in which small vessel disease contributes to their risk of stroke.63 Cilostazol reduced
further strokes in mild (5 vs 16 events; HR = 0.36, 95% CI
= 0.13-0.97, P = 0.04) and moderate (16 vs 32 events; HR
= 0.50, 95% CI = 0.29-0.92, P = 0.03) white matter
changes, which were suggestive of small vessel disease.63 A
meta-analysis of five studies using cilostazol highlighted
that in patients with multiple cerebral microbleeds and
white matter changes, the relative risk of recurrent stroke in
the cilostazol group was significantly lower than in the
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aspirin group (RR = 0.66, 95% CI = 0.54-0.81). It has also
been shown that cilostazol combination therapy (with either
aspirin or clopidogrel) results in lower relative risk of recurrent stroke when compared with aspirin or clopidogrel
alone (RR = 0.50, 95% CI = 0.35-0.72).64 In trials that
have focused on Asian populations, cilostazol combination
therapy (with either aspirin or clopidogrel) has been shown
to be effective in long-term secondary stroke prevention (n
= 10 225; OR = 0.61, 95% CI = 0.52-0.72, P < 0.0001).65
There are a few limitations of the cilostazol clinical trials. Most studies were conducted in East Asia enrolling a
predominantly East Asian population.66 Consequently, the
absence of evidence for an effect in Western populations is
the likely explanation for why cilostazol is not approved by
the American Food and Drug Administration, the UK
Medicines and Healthcare products Regulatory Agency, or
the European Medicines Agency. Future research should
focus on expanding the RCT level evidence for this drug to
other racial groups and patients with small vessel disease,
as the drug appears to have an increased benefit in this subgroup of stroke patients.65 Interestingly, in an RCT trial
investigating the use of cilostazol for the treatment of lacunar stroke (a stroke subtype mainly caused by small vessel
disease without specific treatment guidelines), the use of
cilostazol in combination with isosorbide mononitrate was
well tolerated, evidenced by the fact that 64% of trial participants achieved a full dose 87% achieved a half dose of
isosorbide mononitrate.67 This trial only contained 57 participants though so further larger RCT are needed to confirm this finding.

Glycoprotein IIb/IIIa Inhibitors
The glycoprotein IIb/IIIa inhibitors (GP2b3ais), abciximab,
eptifibatide, and tirofiban have been evaluated for use in the
acute period after ischemic stroke.68 The GP2b3a family of
drugs work to inhibit the platelet cell surface glycoprotein
IIb/IIIa receptor that stops platelet aggregation by inhibiting
fibrinogen molecule binding.69 In general, the drugs are
short-acting and administered intravenously, making them
less appealing for long-term use.70 The GP2b3ais were initially used in the treatment of AIS due to the large body of
evidence of reduced mortality when used to treat myocardial infarction.71
The GP2b3ai with the greatest amount of evidence for use
in AIS is abciximab. Unfortunately, most trials show that the
use of abciximab in AIS dramatically increases the risk of
symptomatic intracranial hemorrhage when given as an
adjunct to thrombolysis.72,73 In fact, the Abciximab in
Emergency Treatment of Stroke Trial (AbESTT-II), n = 808,
was stopped early due to the increased risk of symptomatic or
fatal intracranial hemorrhage within 5 days of enrolment
(5.5% of abciximab-treated vs 0.5% placebo-treated in the
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primary cohort; P = 0.002).72 Evidence from meta-analyses
of GP2b3ai also suggests an increased bleeding risk when
used in AIS, but these studies are biased toward the effect of
abciximab, as this drug has the greatest number of RCTs.73
The combined approach to lysis utilizing eptifibatide and
recombinant tissue-type plasminogen activator (CLEAR)
stroke study (n = 94) evaluated eptifibatide in combination
with tissue plasminogen activator (tPA) and showed that
there is no increased risk of intracranial hemorrhage compared with tPA alone, which was also confirmed by the higher
dose regimen CLEAR-ER trial, n = 126 (OR = 0.15, 95%
CI = 0.01–1.40, P = 0.053).74,75 There have been calls for a
large-scale trial involving eptifibatide as an adjunct to thrombolysis, but this has yet to be performed.76
RCTs that have investigated tirofiban use in AIS suggest
that it may have a benefit similar to that seen with aspirin if
administered within the first 6 hours.77 A lower mortality
rate has been found at 5 months when tirofiban is given in
AIS as compared with placebo (2.3% vs 8.7%, OR = 4.05,
95% CI = 1.1-14.9),78 although no evidence of functional
improvement was seen in the tirofiban group. A recent
meta-analysis has suggested that there is an increased risk
of ICH in people older than the age of 70, those with an
NIHSS score greater than 15 (RR = 1.77, 95% CI = 1.142.73) or those who have been given a dose of 10 mg or
greater of tirofiban (RR = 1.46, 95% CI = 1.07-1.99).68
This may limit the use of tirofiban clinically.
Currently, the AHA/ASA does not support the use of
GP2b3ai for AIS.8 Further studies could be considered for
the drugs eptifibatide and tirofiban, but trial design should
consider their effectiveness in the acute setting when compared with other antiplatelets such as aspirin and clopidogrel, and how age and stroke severity may be contraindications
to their use.
The following table summarizes the data comparing different antiplatelet agents on their effect on secondary stroke
prevention. The NNT and cost per tablet of each drug are
described (see Table 1).

Stroke While on Antiplatelet Therapy
In noncardioembolic stroke and TIA, the guidelines recommend aspirin, either alone or in combination with dipyridamole, or clopidogrel.79 However, no antiplatelet agent
was 100% effective in preventing recurrent cerebrovascular
events in the clinical trials. Furthermore, the phenomenon
of antiplatelet resistance has been well-described.9
While a meta-analysis of observational studies found
evidence in favor of switching to an entirely new antiplatelet combination after a recurrent event, with a reduced incidence of cardiovascular events on follow-up,80 there are no
randomized controlled trials to guide clinicians.
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Table 1. Summary of Antiplatelet Agents and Their Effect on Secondary Stroke Prevention.
Drug
Aspirin

Dipyridamole

Thienopyridines:
Clopidogrel and
ticlopidine

Details

NNT

Aspirin vs placebo
40
Vascular events within 2 years in
patients with TIA/stroke
Aspirin vs placebo
140
Recurrent stroke within 2-4 weeks in
patients with ischemic stroke
Dipyridamole vs placebo
42
Recurrent stroke within 2 years in
patients with TIA/stroke
Dipyridamole + aspirin vs aspirin
37
Vascular events within (mean) 2.6
years in patients with TIA/stroke
Clopidogrel/ticlopidine vs aspirin
100 (not sig)a
Vascular events within (average) 2
years in patients with TIA/stroke

Clopidogrel + aspirin vs aspirin
53
Reduction in all nonfatal recurrent
stroke (ARR 1.9%) in DAPT group.
High-risk TIA/mild stroke patients,
followed up for 90 days
Prasugrel
Prasugrel vs clopidogrel
46
Vascular events after treatment
for 6-15 months in patients
with moderate to high-risk ACS
undergoing PCI
Subgroup analysis of those with
TIA/stroke showed prasugrel has
greater bleeding risk and no net
benefit
Ticagrelor
Ticagrelor vs ticagrelor + aspirin
91
Stroke or death within 30 days in
patients with TIA/stroke
Ticagrelor vs aspirin
125 (not sig)
Vascular events within 90 days
in patients with high-risk TIA/
nonsevere stroke. Ticagrelor not
superior to aspirin.
Cilostazol
Cilostazol vs aspirin
76
Recurrent stroke within follow-up of
between 3 months and 5 years of
patients with TIA/stroke
GP IIb/IIIa inhibitors: No evidence for vascular events in
Abciximab,
stroke population, but secondary
eptifibatide, tirofiban outcomes of stroke recurrence
available in 2 trials

Dose
Aspirin 25 mg BD
Aspirin 160-300 mg

N
6602

Cost as defined by
the BNF
£0.0032 per 75 mg
tablet

40 850

Dipyridamole 200 mg
MR BD

6602

Aspirin 30-990 mg
Dipyridamole 150-400
mg
Clopidogrel 75 mg or
ticlopidine 200-500
mg
Aspirin 325-1300 mg
Clopidogrel 75 mg
(loaded 300-600 mg)
Aspirin 50-325 mg

7612
11 649

£0.17 per 200 mg
tablet

£0.04 per 75 mg
tablet

10 301

Prasugrel 10 mg
(loaded 60 mg)
Clopidogrel 75 mg
(loaded 300 mg)

13 608

£0.19 per 5 mg tablet

Ticagrelor 90 mg BD
+ aspirin 75-100 mg

11 016

£0.98 per 90 mg
tablet

Ticagrelor 90 mg BD
or aspirin 100 mg

13 199

Cilostazol 200 mg
daily
Aspirin 81-300 mg

5681

£0.12 per 100 mg
tablet
Abciximab: NA
Eptifibatide: £13.61
per 20 mg vial
Tirofiban: £159 per
12.5 mg solution

Vascular events: Nonfatal stroke, nonfatal MI, and vascular death.
Abbreviations: ARR, Absolute Risk Reduction; ACS, acute coronary syndrome; BD, twice daily; BNF, British national formulary; CI, confidence
intervals; DAPT, dual antiplatelet therapy; GP, glycoprotein; MI, myocardial infarction; MR, modified release; NA, not available; NNT, numbers needed
to treat; OR, odds ratio; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; TIA, transient ischemic attack.
a
The reduction in odds of vascular events in thienopyridine versus aspirin not statistically significant in the stroke population (OR = 0.94, 95% CI =
0.85-1.03), but was in the overall high-risk vascular population (OR = 0.92, 95% CI = 0.85-0.99), n = 26 255 Clopidogrel and ticlopidine subgroups
performed similarly.
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There are also several other possibilities that need to be
explored if a patient has a stroke despite first-line antiplatelet therapy. First, it is vital to ensure that the patient is adherent with the antiplatelet as prescribed.26 Second, a concurrent
medication review may reveal interacting drugs that need to
be removed. For example, omeprazole can adversely affect
clopidogrel metabolism, so if a proton pump inhibitor (PPI)
is needed, lansoprazole or an alternative PPI should be prescribed instead.81 Third, antiplatelet treatment failure should
prompt the physician to search for cardioembolic causes of
stroke that could respond to anticoagulants rather than antiplatelet agents. Finally, there may be ways to optimize secondary prevention rather than switching antiplatelets, for
example, increasing the dose of statin or improving blood
pressure and/or blood glucose control. Lifestyle modifications should also be aggressively managed in patients who
have had a stroke, as there is strong evidence from the
Stenting and Aggressive Medical Management for
Preventing Recurrent Stroke in Intracranial Stenosis
(SAMMPRIS) study that physical activity prevents further
vascular events.82 In patients who performed regular physical activity such as walking, the odds ratio of a further vascular event (recurrent stroke, myocardial infarction, or
vascular death) was 0.6 (95% CI = 0.4-0.8) compared with
those who did not.
An important consideration is that a proportion of
patients have genetic polymorphisms rendering their platelets resistant to the effects of certain antiplatelets. Several
point-of-care testing (POCT) kits are now available to
detect these polymorphisms, but the testing kits themselves
require further validation before incorporation into randomized trials.9 Until then, it is unclear how POCT can be used
to guide the first choice of antiplatelet, or later switching of
antiplatelets in the face of recurrent events.

Consideration of Dual Antiplatelet
Therapy
As discussed previously in this article, there have been
numerous studies comparing DAPT with single antiplatelet
regimes for various timeframes. The use of DAPT within
the first 21 days poststroke does offer additional benefit for
patients with mild stroke or high-risk TIA.83 Again, the
largest body of evidence comes for the use of clopidogrel
and aspirin in combination. A recent AHA/ASA meta-analysis of dual versus single antiplatelet therapy for stroke prevention in patients with ischemic stroke or TIA concluded
that short-duration DAPT (up to 90 days) initiated soon
after the index event reduced the risk of recurrent stroke
(RR = 0.68, 95% CI = 0.55-0.83), with no significant
increase in major bleeding. In contrast, long-term DAPT
increased the risk of major bleeding with no reduction in
recurrent stroke risk.84 The role of triple antiplatelet therapy
has also been examined. The TARDIS trial (n = 3096),

9
which was stopped early on safety and futility grounds,
found that 30 days of an intensive antiplatelet regime (aspirin, clopidogrel, and dipyridamole) carried significantly
higher bleeding risks, with no commensurate reduction in
stroke recurrence, compared with standard therapy of clopidogrel or aspirin and dipyridamole.85
Aspirin and dipyridamole have been shown to have efficacy as long-term secondary prevention, but in the acute
setting, DAPT comprised of aspirin and clopidogrel remains
the combination of choice. The PRoFESS trial examined
long-term DAPT (aspirin and dipyridamole) versus clopidogrel and found no difference in stroke recurrence rates,
but higher rates of bleeding in the DAPT group.32 While
ticagrelor is not licensed for stroke in the United Kingdom,
the THALES study found that DAPT with aspirin resulted
in fewer strokes at 30 days compared with aspirin alone but
came with a slightly higher bleeding risk.51 Interestingly, in
a recent network meta-analysis, the use of aspirin and clopidogrel (HR = 0.74, 95% CI = 0.65-0.84, n = 5517) or
aspirin and ticagrelor (HR = 0.79, 95% CI = 0.68-0.91, n =
5853) was compared with aspirin alone (n = 10,722) and
found that both DAPT regimes were superior to aspirin
alone at preventing recurrent stroke or death up to 90 days
post treatment initiation (https://pubmed.ncbi.nlm.nih.
gov/34870698/). This again though was at the expense of an
increased risk of major hemorrhage.
The current consensus is that DAPT is appropriate in the
acute phase (defined as the first 30 days poststroke) postischemic stroke, especially when initiated promptly, but
there appears to be no benefit in continuing this further.83
Guidelines from several countries, including the United
States, United Kingdom, and China, recommend commencing DAPT with aspirin plus clopidogrel within 24 hours of
minor stroke (defined as NIHSS ≤3) or high-risk TIA
(defined as ABCD2 ≥ 4, the ABCD2 score being an estimate
of stroke risk after TIA based on patients age, blood pressure, clinical features, duration of symptoms, and presence
of diabetes) and continuing for 21 days.86-88 This is largely
based on the CHANCE and POINT trials that showed that
DAPT with aspirin plus clopidogrel for up to 21 days leads
to a significant reduction in recurrent ischemic stroke at 90
days compared with aspirin monotherapy (RR = 0.70, 95%
CI = 0.61-0.8, NNT = 53), n = 10 301.11,89 Further work
could investigate using several different combinations of
antiplatelet agents which have not been trialed to date.

Using Antiplatelets and Anticoagulants
in Combination
In certain situations, anticoagulant therapy for secondary
prevention of stroke is thought to be beneficial over antiplatelet agents. One such scenario would be the use of anticoagulants poststroke in patients who have atrial fibrillation
(AF).90 The combination of both anticoagulants and
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antiplatelet agents is considered in patients with stroke in
the context of preexisting cardiovascular disease, such as
coronary artery disease in the presence of AF. In this situation, the patient is likely to be started on anticoagulants to
treat the AF poststroke, but the evidence for continuing,
stopping, or adding an antiplatelet agent when coronary
artery disease also exists is less clear. In elderly cohorts (n
= 10 093), it has been shown that there is a small increased
risk of bleeding within 90 days of discharge in patients on
both antiplatelets and anticoagulants (1.3% on only warfarin vs 1.9% on warfarin + antiplatelet, OR = 1.46, 95% CI
= 0.998-2.12),91 but these data are in the context of patients
diagnosed with AF not who have been started on new therapies after stroke. In the GARFIELD-AF cohort study (n =
24 436), it was suggested that when patients are treated with
a combination of both drugs, there is not overall benefit on
all-cause mortality for these patients (adjusted HR = 1.22,
95% CI = 0.98-1.51), suggesting that the risks of increased
bleeding are not outweighed by the benefits.92 Evidence
from the use of combination therapy in patients who have
unstable coronary artery disease may suggest that shortterm antiplatelets improve patient outcome, but the benefit
is reduced when the drugs are used more long-term.93 In this
scenario, clopidogrel is thought to be the most efficacious
antiplatelet to use in combination with anticoagulation.94
When combination therapy has been investigated as a comparator to antiplatelet agents for all causes of stroke, no
additional benefit was seen of using combination therapy,
except when low-dose unfractionated heparin and aspirin
were used in combination (OR = 0.75, 95% CI = 0.561.03), but this interaction warrants further investigation
before firm conclusions can be made as reduction seen in
recurrent stroke risk was not significant.95 It has also been
investigated if the use of heparin in addition to standard
therapy improves outcome in the first 6 months poststroke,
and again no additional benefit was observed.96
When generalizing to the ischemic stroke population,
there appears to be little benefit of combination therapy.
The caveat to this though may be that in certain situations
when a patient presents with stroke and unstable coronary
artery disease, the use of combinations of antiplatelets and
anticoagulant drugs may provide extra benefit. Currently,
there is no RCT level evidence of the benefits of combination therapy poststroke assessing this particular group and
is an important area for future research to investigate.

Relevance to Patient Care and Clinical
Practice
Several strategies could be considered to improve the use of
antiplatelet agents in the treatment of stroke in future
research trials and clinical practice. It appears that in the
vast majority of cases, the long-term secondary prevention
of stroke is best managed using either clopidogrel or aspirin. In the acute setting, there are several issues that
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potentially could be improved using alternative antiplatelet
agents. When considering these issues, the application of a
personalized medicine approach to the treatment of stroke
with antiplatelets should be considered.
There is a large body of evidence to suggest that certain
platelet genetic polymorphisms can render patients resistant
to treatment with either clopidogrel or aspirin. Given the
strong evidence base for the use of aspirin and clopidogrel
in AIS and in secondary prevention, screening for these
polymorphisms upon initial stroke presentation could be
considered when personalizing the approach to antiplatelet
use. These results could inform whether to consider combination therapy, switch antiplatelet agent, or increase the
aspirin dose, although these options must be balanced
against the risk of bleeding, drug adverse effects, and the
possibility of resistance to other antiplatelet medications.
The greatest risk of recurrent stroke is within the first 30
days of the initial event. Therefore, in future clinical settings, as genetic phenotyping becomes more accessible, this
may be done as part of the initial stroke assessment. This
would allow the stroke physician to then make a more
informed decision as to which antiplatelet agent to use in
cases of clopidogrel or aspirin resistance.
Biochemical response to aspirin and clopidogrel can be
measured through in vitro tests such as platelet function
analysis (PFA) tests, light transmission aggregometry, and
by in vivo quantification of thromboxane metabolites.
However, there is poor correlation between the different
assay results in each individual subject.24 The variety of
proposed mechanisms and lack of consensus regarding best
screening modality means that there is no current single test
to reliably determine which patients are likely to experience
aspirin treatment failure, thereby requiring clinical judgment about ongoing treatment strategy if aspirin treatment
failure were to occur currently.
Within the acute setting, decisions about the use of certain antiplatelets in combination with thrombolysis/thrombectomy and which combination of antiplatelets to use as
part of DAPT could be reviewed as part of future clinical
trials. There is evidence that certain antiplatelet agents may
improve outcome when used in conjunction with thrombolysis in the acute setting (eptifibatide, glycoprotein IIb/IIIa
inhibitor, potentially being one of these drugs). When considering the use of DAPT in the initial secondary prevention
of stroke, it should also be considered that not all combinations of antiplatelets have been researched, and so better
combinations may still be found. However, it is important to
remember that there appears to be more risk than benefit to
extending DAPT beyond 21 days. Most of the research for
the use of clopidogrel and aspirin as part of DAPT focuses
on Western and Chinese populations; therefore, it may be
that patients of different ethnicities respond better to other
combinations of antiplatelets in this acute phase.
Race should also be considered when planning future
long-term therapy trials for the secondary prevention of
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stroke. There is evidence already that stroke type, incidence,
and risk factors differ among ethnic groups;97 therefore, secondary prevention of stroke is likely to be confounded by
this. Although there is very good evidence for the use of
clopidogrel and aspirin in the long-term prevention of stroke,
there is a signal that other antiplatelets may have additional
benefits to nonwhite populations (cilostazol is a potential
example of this in Japanese populations). Ticagrelor and
prasugrel do not rely on the activity of CYP2C19 and therefore may also have increased benefits over clopidogrel in
East Asian populations known to have a higher carrier frequency of the CYP2C19 loss-of-function allele.60
Antiplatelet stroke research, like many other areas of clinical
research, should try to develop clinical trial level evidence in
populations around the world that are not a majority white.
This will help to develop a personalized medicine approach
to the treatment of stroke which will benefit all stroke
patients, but also potentially help to address the racial disparities unfortunately seen in stroke care.98
Finally, strategies aimed at improving patient adherence
to prescribed drugs should also be considered. One of the
largest factors affecting the efficacy of antiplatelet agents in
the secondary prevention of stroke is patient nonadherence
with medications.26 It has been suggested the noncompliance with the use of antiplatelet agents can be as high as
35% twelve months postischemic stroke. There are several
factors that are thought to affect this, including being older
than the age of 70 years old, already taking multiple medications (>4 drugs), coming from a lower social economic
class and being from a more rural community.99 In Englishspeaking communities, having a poorer proficiency in
English has been associated with reduced antiplatelet adherence, as has having multiple medical comorbidities.100
Strategies aimed at improving awareness of the side effects
of antiplatelet agents, endowing patients with more knowledge about why they are taking the drug, and having access
to appropriate medication counseling have been shown to
be factors that can be addressed to improve patient antiplatelet adherence.101

Conclusion
Antiplatelet agents remain one of the most efficacious
and best researched secondary preventive measures for
the treatment of stroke. The use of both clopidogrel and
aspirin is well established in both the acute and secondary
prevention settings and is the basis of most clinical guidelines around the world. Although there is already good
evidence for the appropriate use of antiplatelets postischemic stroke, future research may focus on how to personalize the approach to antiplatelet prescription. This may
take the form of screening patients for platelet polymorphisms that confer antiplatelet resistance or extending
randomized controlled trial level evidence to be more
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encompassing of the diverse racial populations that are
affected by stroke.
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